vTv Therapeutics Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||
| 2024 | 2023(*) | 2022(*) | |||||||||||||||
| Numerator: | |||||||||||||||||
| Net loss | $ | (22,705) | $ | (25,966) | $ | (25,073) | |||||||||||
| Less: Net loss attributable to noncontrolling interests | (4,243) | (5,716) | (5,909) | ||||||||||||||
| Net loss attributable to vTv Therapeutics Inc. | (18,462) | (20,250) | (19,164) | ||||||||||||||
| Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted | $ | (18,462) | $ | (20,250) | $ | (19,164) | |||||||||||
| Denominator: | |||||||||||||||||
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (1) | 5,771,052 | 2,084,973 | 1,919,788 | ||||||||||||||
| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $ | (3.20) | $ | (9.71) | $ | (9.98) | |||||||||||
(*) Adjusted retroactively for reverse stock split, see Note 1 | |||||||||||||||||
| (1) | The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the year ended December 31, 2024. | |||||||
| Year Ended December 31, | |||||||||||||||||
| 2024 | 2023(*) | 2022(*) | |||||||||||||||
Class B common stock (1) (*) | 577,349 | 577,349 | 577,349 | ||||||||||||||
Common stock options granted under the Plan (*) | 705,593 | 249,247 | 208,586 | ||||||||||||||
Common stock warrants (*) | 70,639 | 76,545 | 80,359 | ||||||||||||||
Total (*) | 1,353,581 | 903,141 | 866,294 | ||||||||||||||
(*) Adjusted retroactively for reverse stock split, see Note 1 | |||||||||||||||||
Want the next vTv Therapeutics Inc. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment vTv Therapeutics Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.